Delaying elective neck irradiation reduces early lymphocyte damage but not eventual lymphopenia

Delayed elective nodal irradiation reduced early lymphocyte DNA damage approximately fourfold and postponed lymphopenia onset without improving its eventual severity.

KEY POINTS

  • This prospective randomized study included 28 patients with locally advanced head and neck squamous cell carcinoma, receiving definitive chemoradiotherapy (n=15) or postoperative RT with or without chemotherapy (n=13). Patients were assigned to standard elective nodal irradiation (ENI; n=15) or delayed ENI (n=13).
  • Delayed ENI began with irradiation restricted to gross disease or high-risk postoperative regions before standard elective volumes were introduced. This upfront boost lasted 5 × 2 Gy in definitive treatment and 2 × 2 Gy in the adjuvant setting, followed by the usual elective irradiation schedule.
  • Delaying ENI reduced the initial PTV by 9.9-fold and mean whole-body dose by 4.4-fold (both p<0.001). Radiation-induced γH2AX/53BP1 DNA-damage foci in peripheral lymphocytes were approximately fourfold lower after the first fraction (p<0.001) and threefold lower at 24 hours.
  • The proportion of lymphocytes with radiation-associated DNA damage after fraction one was 10.9 ± 6.5% with delayed ENI versus 23.3 ± 9.8% with standard ENI (p<0.001). In the definitive-treatment subset, dicentric chromosome frequencies before fraction six were approximately fourfold lower after delayed ENI (p<0.05).
  • Lymphocyte counts remained near baseline during the first treatment week with delayed ENI, whereas standard ENI produced an immediate decline. After elective irradiation began, counts also fell in the delayed group; by week two, lymphopenia incidence was 58% with standard ENI versus 61% with delayed ENI, and all patients eventually developed lymphopenia.
  • Lymphopenia onset differed significantly between treatment strategies (p=0.04), but nadir severity did not (p=0.44). Grade 4 lymphopenia was numerically more frequent after standard ENI (21% vs 8%), without statistical significance.
  • Exploratory leukocyte RNA sequencing in only four patients, two per group, suggested greater enrichment of interferon-α/γ and metabolic signaling after delayed ENI, compared with inflammation-related pathways after standard ENI. These exploratory signatures do not demonstrate improved antitumor immunity or greater immunotherapy efficacy.

CLINICAL TAKEAWAY

Temporarily limiting elective nodal irradiation during the initial fractions of head and neck RT can markedly reduce circulating lymphocyte DNA damage and delay lymphopenia onset, providing a biological rationale for immune-sparing sequencing. However, lymphopenia eventually occurred in all patients, and the study does not demonstrate improved clinical toxicity, oncological outcomes, or immunotherapy efficacy.

SOURCE

Clinical and Translational Radiation Oncology

Browse more research Suggest a correction